ClinicalTrials.gg
Active, not recruitingNCT01871766Updated Jun 17, 2026

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

A Phase 2 interventional study of Vincristine and Dactinomycin in Rhabdomyosarcoma, sponsored by St. Jude Children's Research Hospital. Active, not recruiting at 4 sites in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Non-randomized
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital — 6 open to participants now, 9 under way, none of them phase 3. Rhabdomyosarcoma · St. Jude Children's Research Hospital.

Enrollment
5th of 14
115 · median 94
Started
2013
the only one that year
Phase 2
4 of 17
1 open now
Registered
10th of 17
by date

Among the 17 studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2013, is one of 4 in phase 2, and was the 10th registered.

Rhabdomyosarcoma

238 studies on the registry are indexed under Rhabdomyosarcoma; 49 are open to participants now.

Browse Rhabdomyosarcoma studies →

Open to participants now

6 of the 17 studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 39 Rhabdomyosarcoma studies recruiting now, 8 (21%) set no upper age limit and 31 (79%) stop at 75 or younger; 35 take children under 18; none take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Rhabdomyosarcoma by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

This study will treat participants with newly diagnosed, low, intermediate and high risk rhabdomyosarcoma (RMS) using multi-modality risk-adapted therapy with standard or intensified dose chemotherapy, radiation and surgical resection. Intermediate and high risk participants will receive an additional 12 weeks (4 cycles) of maintenance therapy with anti-angiogenic chemotherapy.

PRIMARY OBJECTIVE:

  • Estimate event-free survival for intermediate risk participants treated with vincristine, dactinomycin and cyclophosphamide with the addition of maintenance anti-angiogenic therapy.

SECONDARY OBJECTIVES:

  • Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.
  • Maintain a high local control rate in participants treated with surgery and/or limited volume proton and photon radiation without dose escalation.
  • Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume.
  • Establish the feasibility of delivering 4 cycles of maintenance anti-angiogenic chemotherapy in intermediate and high risk patients following standard chemotherapy.
  • Estimate the event free survival for high risk patients receiving interval dose compressed therapy and maintenance anti-angiogenic therapy.
  • Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy.
Read the detailed description

Participants will be stratified based on both a pretreatment staging system and a post-surgery surgico/pathologic clinical grouping system. Treatment for low-risk (subset 1) participants will consist of chemotherapy and radiation. Low-risk (subset 2) and intermediate-risk participants will receive chemotherapy and radiation and/or undergo surgery to destroy/remove the tumor. Intermediate-risk participants will also receive 16 weeks of maintenance chemotherapy. High-risk participants will receive chemotherapy and radiation therapy. High-risk participants will also receive additional maintenance therapy with anti-angiogenic chemotherapy.

03

Conditions studied

  • Rhabdomyosarcoma

Browse trials for

Keywords

  • Rhabdomyosarcoma
  • Radiation therapy
  • Proton beam
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Newly diagnosed participants with localized rhabdomyosarcoma (RMS).
  • Must have either low-, intermediate-, or high-risk disease, defined as:

    • Low-risk: Embryonal, botryoid, spindle cell tumors only (Subset 1: Stage 1, Group I; Stage 1 Group I; Stage 1 Group III orbital only; Stage 2 Group I; Stage 2 Group II) (Subset 2: Stage 1 Group III non orbit; Stage 3 Group I, II)
    • Intermediate-risk: Embryonal, botryoid, or spindle cell RMS Stage 2 or 3 and Group III; Alveolar, undifferentiated, or anaplastic RMS: Stage 1-3, group I-I; I)
    • High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or anaplastic RMS with disease at diagnosis (stage 4).
    • Participants treated on this protocol in the low or intermediate risk arm who experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocol.
  • Age \< 22 years (eligible until 22nd birthday)
  • Performance level corresponding to score of 0, 1, or 2. The Lansky performance score should be used for participants \< 16 years
  • Participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma (excluding ) unless an emergency situation requires local tumor treatment. Prior , surgical resection and lymph node sampling is allowed.
  • Initiation of chemotherapy is planned within 6 weeks (42 days) of the definitive biopsy or surgical resection.
  • Adequate bone marrow function defined as:

    • Peripheral (ANC) ≥ 750/μL
    • count ≥ 75,000/μL (transfusion independent)
  • Adequate liver function defined as total ≤ 1.5 x (ULN) for age. Participants with biliary or hepatic primaries with bilirubin values greater than 1.5 x ULN may be enrolled on study if all other eligibility criteria are met.
  • Adequate renal function defined as:

    • or radioisotope ≥ 70 mL/min/1.732 or
    • Serum creatinine based on age and gender
    • Participants with urinary tract obstruction by tumor must meet the renal function criteria listed above AND must have unimpeded urinary flow established via decompression of the obstructed portion of the urinary tract.
  • Patients requiring emergency radiation therapy are eligible for enrollment on this study.
  • Females of cannot be pregnant or breast-feeding. Female participants ≥ 10 years of age or post-menarchal must have a negative serum or urine pregnancy test within 24 hours prior to beginning treatment. Female participants who are breast feeding must agree to stop breast feeding.
  • Sexually active patients of childbearing potential must be willing to use effective during therapy and for at least 1 month after treatment is completed.
  • No evidence of active, uncontrolled infection.
  • All participants and/or their parents or legal guardians must sign a written .

Exclusion Criteria:

  • Participants who fail to meet one or more of the inclusion criteria will be excluded.

Inclusion Criteria for Contrast-Enhanced Ultrasound (CEUS) Sub-Study:

  • Newly diagnosis or suspected diagnosis of previously untreated participants with rhabdomyosarcoma (RMS). NOTE: Patients with suspected diagnosis of RMS may enroll on screening part of study but must have histologic diagnosis to enroll on treatment part of study.
  • Must have either intermediate-risk or high risk disease.
  • 0-21 years of age.

Exclusion Criterial for CEUS Sub-Study:

  • Undergoing upfront surgical resection of the primary tumor.
  • History of allergy to Optison(TM) contrast agent or blood products.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Low-Risk, Subset 1

    Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin and cyclophosphamide). They are then evaluated to determine how the tumor responded to treatment. Twelve additional weeks of chemotherapy (vincristine and dactinomycin) is given, followed by evaluation for tumor response. No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed. Participants also receive \^1\^1C-methionine as described in the intervention section.

    Drug: Vincristine · Drug: Dactinomycin · Drug: Cyclophosphamide · Procedure: Surgical Resection · Procedure: Radiation · Drug: Myeloid Growth Factor · Procedure: Lymph Node Sampling · Drug: ^1^1C-methionine

  • Experimental
    Low-Risk, Subset 2

    Lymph node sampling will take place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated to determine how it responded to treatment. Radiation therapy and/or surgical resection is performed to destroy or remove the remaining tumor. Twelve additional weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is given, followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants then receive 16 weeks of additional chemotherapy (vincristine, dactinomycin and cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor will be given if needed. Participants also receive \^1\^1C-methionine as described in the intervention section.

    Drug: Vincristine · Drug: Dactinomycin · Drug: Cyclophosphamide · Procedure: Radiation · Drug: Myeloid Growth Factor · Procedure: Lymph Node Sampling · Drug: ^1^1C-methionine

  • Experimental
    Intermediate-Risk

    Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 12 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide). The tumor is evaluated for treatment response. Radiation therapy and/or surgical resection is done. Twelve weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) is followed by evaluation for tumor response. If delayed for medical reasons, radiation therapy and/or surgical resection is done at this time. Participants receive 16 weeks of chemotherapy (vincristine, dactinomycin, cyclophosphamide) followed by 12 weeks of maintenance treatment (bevacizumab, sorafenib, oral cyclophosphamide). No further treatment is given, and participants are observed closely. Myeloid growth factor is given if needed. Participants also receive \^1\^1C-methionine as described in the intervention section.

    Drug: Vincristine · Drug: Dactinomycin · Drug: Cyclophosphamide · Procedure: Surgical Resection · Procedure: Radiation · Drug: Bevacizumab · Drug: Sorafenib · Drug: Myeloid Growth Factor · Procedure: Lymph Node Sampling · Drug: ^1^1C-methionine

  • Experimental
    High-Risk

    Lymph node sampling takes place pretreatment and pre-surgery. Participants receive 6 weeks (2 cycles) chemotherapy (vincristine and irinotecan). The tumor is evaluated for treatment response. 3 cycles of chemotherapy \[vincristine, doxorubicin, cyclophosphamide/ifosfamide, etoposide (or etoposide phosphate) (VDC/IE)\] are given. Dexrazoxane is given prior to each dose of doxorubicin. Radiation therapy begins at week 4 or 20 (depending on tumor location) while receiving vincristine and irinotecan. 2 cycles of VDC/IE, 4 cycles of modified vincristine, dactinomycin, cyclophosphamide (VAC), then 2 cycles of modified vincristine/irinotecan (total of 54 weeks). High risk participants also receive additional maintenance therapy beginning week 55 with anti-angiogenic chemotherapy (bevacizumab, sorafenib, cyclophosphamide). Myeloid growth factor is given as needed. Participants also receive \^1\^1C-methionine as described in the intervention section.

    Drug: Vincristine · Drug: Dactinomycin · Drug: Cyclophosphamide · Procedure: Surgical Resection · Procedure: Radiation · Drug: Bevacizumab · Drug: Sorafenib · Drug: Myeloid Growth Factor · Procedure: Lymph Node Sampling · Drug: Irinotecan · Drug: Ifosfamide · Drug: Etoposide · Drug: Etoposide Phosphate · Drug: Doxorubicin · Drug: Dexrazoxane · Drug: ^1^1C-methionine

Interventions

  • Dosage and route of administration: * \< 1 year of age=0.025 mg/kg intravenously (IV) * \> 1 year and \< 3 years= 0.05 mg/kg IV * ≥ 3 years=1.5 mg/m\^2 IV. Maximum dose 2 mg in all participants.

    Also known as: Oncovin®

  • Dosage and route of administration: * \< 1 year=0.025 mg/kg IV push * ≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes.

    Also known as: Actinomycin-D, Cosmegen®

  • Dosage and route of administration: During VAC chemotherapy: * \< 3 years of age = 40 mg/kg IV * ≥ 3 years of age = 1200 mg/m\^2 IV, with MESNA. During maintenance for intermediate-risk participants: * oral cyclophosphamide 50 mg/m\^2/dose/day (liquid or tablet)

    Also known as: Cytoxan(R)

  • ProcedureSurgical Resection

    Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.

    Also known as: Surgery

  • ProcedureRadiation

    Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.

    Also known as: Proton Beam Radiation, External Beam Radiation, Brachytherapy

  • Dosage and route of administration: 15 mg/kg/dose/day IV.

    Also known as: rhuMab, VEGF, Avastin®

  • Dosage and route of administration: 90 mg/m\^2/dose twice daily.

    Also known as: Nexavar®

  • DrugGranulocyte Colony-Stimulating FactorStudies of Granulocyte Colony-Stimulating FactorGranulocyte Colony-Stimulating Factor pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice. High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used.

    Also known as: G-CSF, Filgrastim, Pegfilgrastim

  • ProcedureLymph Node Sampling

    Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in "at risk" patients.

  • Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m\^2 IV (maximum dose 100 mg/day) daily x 5.

    Also known as: Camptosar ®

  • Dosage and Route of Administration: During interval compressed therapy - Age \> 1 year: 1800 mg/m\^2/day IV x 5 Age \<1 year: treat with 50% doses calculated on a m\^2 basis.

    Also known as: Ifex ®

  • Dosage and Route of Administration: Age \>1 year 100 mg/m\^2/day IV x 5 Age \< 1 year treat with 50% doses calculated on a m\^2 basis

    Also known as: VP-16, Vepesid®

  • Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m\^2/day IV.

    Also known as: Etopophos®

  • Dosage and route of Administration: Age ≥1 year, 37.5 mg/m\^2 IV over 1 hour x 2 days Age \<1 year, 18.75 mg/m\^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days.

    Also known as: Adriamycin®

  • Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin. Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes.

    Also known as: Zinecard

  • Drug^1^1C-methionine

    Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.

    Also known as: Contrast Media

06

What researchers measure

Primary outcomes

  1. Event-free survival (intermediate risk arm)

    To estimate event-free survival for intermediate risk participants treated by vincristine-dactinomycin-cyclophosphamide (VAC) with the addition of maintenance anti-angiogenic therapy

    Time frame: 2 years after last intermediate risk arm enrollment

Secondary outcomes

  1. Event-free survival (high risk arm)

    To estimate event-free survival for high risk participants.

    Time frame: 5 years after last high-risk arm enrollment

  2. Rate of false negative and false positive the sentinel lymph node procedure (low and intermediate risk arms)

    Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.

    Time frame: 2 years after last low or intermediate arm enrollment

  3. Rate of false negative and false positive the sentinel lymph node procedure (high risk arm)

    Estimate the false negative rate and incidence of additional positive lymph nodes in participants undergoing sentinel lymph node biopsy followed by limited nodal dissection.

    Time frame: 5 years after last high risk arm enrollment

  4. Local failure rate (low and intermediate risk arms)

    Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation

    Time frame: 2 years after last low or intermediate risk arm enrollment

  5. Local failure rate (high risk arm)

    Maintain a high local control rate in participants treated with surgery and / or limited volume proton and photon radiation without dose escalation

    Time frame: 5 years after last high risk arm enrollment

  6. Patterns of failure (low and intermediate risk arms)

    Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume

    Time frame: 2 years after last low or intermediate risk arm enrollment

  7. Patterns of failure (high risk arm)

    Define the incidence and type of failure in participants who receive risk-adapted local therapy relative to the primary tumor volume

    Time frame: 5 years after last high risk arm enrollment

  8. Number of patients that complete all cycles of maintenance chemotherapy (intermediate risk arm)

    Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in intermediate risk patients following standard chemotherapy.

    Time frame: 2 years after last low or intermediate risk arm enrollment

  9. Number of patients that complete all cycles of maintenance chemotherapy (high risk arm)

    Establish the feasibility of delivering 4 cycles of maintenance antiangiogenic chemotherapy (bevacizumab / sorafenib / low dose cyclophosphamide) in high risk patients following standard chemotherapy.

    Time frame: 5 years after last high risk arm enrollment

  10. Incidence of CTC grade 3 and higher toxicities related to proton bream therapy (low and intermediate and high risk arms)

    Define the incidence of CTC grade 3 and higher toxicities (and specific grade 1-2 toxicities) related to proton beam therapy.

    Time frame: 2 years after last enrollment

07

Study locations

4 sites
08

References and documents

Publications

  • Patel AG, Chen X, Huang X, Clay MR, Komorova N, Krasin MJ, Pappo A, Tillman H, Orr BA, McEvoy J, Gordon B, Blankenship K, Reilly C, Zhou X, Norrie JL, Karlstrom A, Yu J, Wodarz D, Stewart E, Dyer MA. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. Dev Cell. 2022 May 23;57(10):1226-1240.e8. doi: 10.1016/j.devcel.2022.04.003. Epub 2022 Apr 27. PubMed 35483358 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2013 (actual). Primary completion is estimated for Dec 2026, 156 months after the start.

Of 36 non-industry phase 2 interventional studies under Rhabdomyosarcoma, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 156 months is above that.

Counting every sponsor, half of 39 studies reached it within 63 months; a quarter within 40 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2013
First posted
Jun 7, 2013
StartActual
Dec 4, 2013
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2030
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01871766
Responsible party
Sponsor
First posted
Jun 7, 2013
Start date
Dec 4, 2013
Primary completion
Dec 2026 (estimated)
Completion
Jun 2030 (estimated)
Last update
Jun 17, 2026

Study contacts

Matthew J. Krasin, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Sorafenib · Irinotecan · Ifosfamide · Etoposide · Etoposide phosphate · Doxorubicin · Dexrazoxane

Start the discussion